Daily Cardiology Research Analysis
Analyzed 63 papers and selected 3 impactful papers.
Summary
Three impactful cardiology papers emerged today: a mechanistic study identifies endothelial-to-mesenchymal transition as a driver of right ventricular endocardial fibroelastic remodeling in pulmonary atresia/critical pulmonary stenosis with intact ventricular septum, suggesting new anti-fibrotic targets. A nationwide Swedish registry using instrumental variable analysis reaffirms no survival benefit and higher complications with intra-aortic balloon pump in MI-related cardiogenic shock. The WARRIOR randomized trial in women with suspected INOCA found no reduction in major adverse events with intensive medical therapy versus usual care, with outcomes dominated by angina hospitalizations.
Research Themes
- Fibrogenesis and endothelial-to-mesenchymal transition in congenital heart disease
- Mechanical circulatory support in cardiogenic shock
- Management strategies for INOCA/ANOCA in women
Selected Articles
1. Fibroelastic remodeling of the endocardium on the right side of the heart: Endothelial-to-mesenchymal transition in pulmonary atresia with intact ventricular septum.
Using patient tissues and in vitro flow models, the authors show that disturbed flow in PA/cPS-IVS triggers endothelial-to-mesenchymal transition in endocardial endothelial cells, driving subendocardial fibroelastic remodeling and right ventricular diastolic dysfunction. This identifies fibrogenic pathway activation via EndMT as a potential therapeutic target.
Impact: This is a mechanistic, translational study revealing a previously underappreciated driver of right-sided endocardial pathology, opening avenues for anti-fibrotic interventions in a challenging congenital population.
Clinical Implications: Suggests evaluating anti-fibrotic and anti-EndMT strategies (e.g., TGF-β/SMAD modulation) and optimizing valvular flow early to prevent/remodel RV diastolic dysfunction in PA/cPS-IVS.
Key Findings
- All 13 PA/cPS-IVS patients exhibited disturbed flow across pulmonary and/or tricuspid valves.
- Resected right ventricular tissue showed active subendocardial fibroelastic remodeling infiltrating myocardium.
- Patients demonstrated RV diastolic dysfunction with elevated filling pressures.
- Pathological flow induced EndMT in isolated endocardial endothelial cells, with loss of endothelial markers and mesenchymal transition.
Methodological Strengths
- Multimodal tissue analysis (histology, immunohistochemistry, flow cytometry) with endothelial lineage-focused assays
- Disease-mimicking in vitro flow models linking hemodynamics to cellular EndMT mechanisms
Limitations
- Small single-center cohort (n=13) limits generalizability
- No interventional proof that EndMT inhibition reverses RV dysfunction in vivo
Future Directions: Test anti-EndMT/anti-fibrotic agents in preclinical PA/cPS-IVS models; integrate patient-specific hemodynamic simulations to guide early surgical/interventional strategies; develop biomarkers of active EndMT for risk stratification.
OBJECTIVES: Patients with pulmonary atresia/critical pulmonary stenosis with intact ventricular septum (PA/cPS-IVS) show fibrous subendocardial tissue of unclear origin accompanied by right ventricular (RV) hypoplasia. While in hypoplastic left heart syndrome it is known that flow-induced endothelial-to-mesenchymal transition (EndMT) of endocardial endothelial cells (EECs) is the source of this fibrous tissue, it remains unclear whether similar mechanisms exist in PA/cPS-IVS. METHODS: We analyzed 13 PA/cPS-IVS patients who underwent staged ventricular rehabilitation surgery aimed at preserving RV function between March 2021 and July 2025 at Boston Children's Hospital. Resected tissue was examined for the degree of fibrosis and elastin, and the presence of active EndMT by histology, immunohistochemistry, and flow cytometry. To mimic human disease conditions, isolated EECs were exposed to pathological flow and compared with physiological flow conditions. RESULTS: Flow disturbances across the pulmonary and/or tricuspid valves were present in all patients. Resected RV tissue revealed an active subendocardial fibroelastic remodeling process, infiltrating into the underlying myocardium. Patients showed RV diastolic dysfunction, as evidenced by elevated filling pressures, suggesting a pathophysiological role of fibroelastic remodeling of the endocardium. Mimicking the human disease, exposure of isolated EECs to pathological flow conditions induced loss of endothelial characteristics and transition toward a mesenchymal phenotype through EndMT. CONCLUSIONS: In PA/cPS-IVS patients, restrictive RV physiology and diastolic dysfunction are likely driven by infiltrative fibroelastic remodeling caused by localized fibrogenic activation of EECs through EndMT in response to flow disturbances from valvular defects. Fibrogenic pathway activation may represent a promising therapeutic target in PA/cPS-IVS.
2. Intra-aortic balloon support for myocardial infarction with cardiogenic shock: insights from the Swedish Coronary Angiography and Angioplasty Registry.
In 2,991 Swedish MI-related cardiogenic shock patients, intra-aortic balloon pump support did not reduce 30-day or 1-year mortality but was associated with a 26.1% absolute increase in in-hospital complications using an instrumental variable approach. These findings reinforce guideline recommendations against routine IABP use in this setting.
Impact: Large, nationwide real-world evidence with causal inference methods clarifies harm without benefit of a common MCS strategy in shock, directly informing acute care decisions.
Clinical Implications: Avoid routine IABP in MI-related cardiogenic shock; prioritize early revascularization, pharmacologic support, and consider alternative MCS selectively with attention to complication risk.
Key Findings
- Instrumental variable analysis (hospital IABP preference) showed no mortality reduction at 30 days (risk reduction -1.1%, P=0.881) or 1 year (risk reduction -0.8%, P=0.258).
- IABP use was associated with a 26.1% absolute increase in in-hospital complications (P<0.001).
- Overall mortality remained high: 52% at 30 days and 63.2% at 1 year in MI-related cardiogenic shock.
Methodological Strengths
- Nationwide, multicenter prospective registry over 13 years with large sample size
- Instrumental variable approach to mitigate confounding by indication
Limitations
- Observational design with potential residual confounding and time-trend device/practice changes
- Limited granularity on shock severity, timing of support, and co-interventions
Future Directions: Define patient phenotypes that may benefit from alternative MCS; conduct pragmatic trials comparing contemporary MCS strategies; refine complication mitigation protocols.
BACKGROUND: Cardiogenic shock remains the leading cause of in-hospital death in patients with acute myocardial infarction (MI). The intra-aortic balloon pump (IABP), once widely used, was downgraded in European guidelines after a major randomized trial showed no mortality benefit. This prospective observational study evaluated the impact of IABP on 30-day mortality and in-hospital complications in real-world patients with MI complicated by cardiogenic shock. METHODS: Data were obtained from the Swedish Coronary Angiography and Angioplasty Registry, including all percutaneous coronary intervention procedures performed across 31 hospitals in Sweden between 2005 and 2018. A total of 2991 patients with cardiogenic shock were included, of whom 737 (25%) received IABP. To account for baseline differences, instrumental variable analysis was applied using hospital treatment preference as the instrument. RESULTS: At 30 days, 52% of patients had died, and by 1 year, mortality reached 63.2%. In-hospital complications occurred in 13.4% of patients. IABP treatment was not associated with reduced mortality at 30 days [risk reduction: -1.1%, 95% confidence interval (CI): -15.7 to 13.5; P = 0.881] or at 1 year (risk reduction: -0.8%, 95% CI: -23.2 to 0.06; P = 0.258). However, IABP use was associated with a significantly higher risk of in-hospital complications (increase of 26.1%, 95% CI: 15.2-36.8; P < 0.001). CONCLUSION: IABP did not improve short- or long-term survival in patients with MI-related cardiogenic shock but was linked to increased complications, supporting current guideline recommendations against its routine use.
3. Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a randomised controlled trial.
In 2,476 women with suspected INOCA randomized to intensive medical therapy (high-intensity statin, ACEi/ARB, aspirin) versus usual care, there was no reduction in MACE over 2.5 years (HR 1.13). Outcomes were dominated by angina hospitalizations, highlighting symptom burden and resource use.
Impact: Provides randomized evidence in a large, under-studied population, delivering a robust negative result that will recalibrate expectations for blanket IMT in suspected INOCA and refocus research on targeted pathophysiology-driven strategies.
Clinical Implications: Routine addition of high-intensity statin, ACEi/ARB, and aspirin for all suspected INOCA women may not reduce MACE; care should emphasize individualized endotype testing, symptom control, risk factor optimization, and reduce avoidable angina hospitalizations.
Key Findings
- No significant reduction in MACE with intensive medical therapy versus usual care over 2.5 years (HR 1.13, 95% CI 0.94–1.37; p=0.20).
- Hospitalizations for angina were the dominant component of the composite outcome.
- Baseline risk factors were well controlled and background statin and ACEi/ARB use were relatively high, with trial underpowered due to lower-than-planned enrollment.
Methodological Strengths
- Randomized, multicenter design with blinded outcome adjudication
- Female-specific, large cohort addressing an important evidence gap
Limitations
- Underpowered due to reduced enrollment and treatment contamination
- Composite endpoint driven mainly by angina hospitalizations, potentially diluting hard event effects
Future Directions: Focus trials on mechanistic endotypes (microvascular dysfunction, vasospasm, CMD-guided therapies), patient-centered outcomes, and strategies to prevent recurrent angina hospitalizations; consider adaptive designs and precision therapeutics.
IMPORTANCE: Women with angina due to suspected ischaemia referred for coronary angiography often have no obstructive coronary artery disease (ANOCA/INOCA). OBJECTIVE: To determine if intensive medical treatment (IMT) reduces major ischaemic events (major adverse cardiovascular event, MACE) among women with suspected ANOCA/INOCA. DESIGN: Randomised, prospective, blinded-outcomes evaluation. SETTING: 71 sites in the USA. PARTICIPANTS: 2476 women with suspected ANOCA/INOCA. INTERVENTIONS: IMT-high intensity statin, ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) and aspirin versus usual care (UC). MAIN OUTCOMES AND MEASURES: Primary: all cause death, myocardial infarction, stroke/transient ischaemic attack, hospitalisation for angina or heart failure (MACE). Secondary: components of the primary, quality of life and win ratio. RESULTS: Recruitment was lower than planned (n=2476), yielding an aged population (mean, 64 years) with well-controlled blood pressure and low-density lipoprotein cholesterol at baseline, and relatively high rates of statin and ACEI/ARB use. At 2.5 years, 421 events occurred (221 in IMT, 200 in UC) with no difference in the primary outcome (HR=1.13 (95% CI 0.94 to 1.37) for IMT vs UC, p=0.20) or secondary outcomes. Hospitalisations for angina were the dominant contributor to MACE. Sensitivity analysis of contamination provided an estimated HR for IMT versus UC of 0.74 95% CI (0.352 to 1.558), p=0.43. CONCLUSIONS AND RELEVANCE: Among women with suspected ANOCA/INOCA, outcomes were dominated by chest pain and IMT did not improve outcomes, although limited power precludes concluding that it may not be helpful. The findings support the need for more investigation in this population with high burden of angina hospitalisation, health resource consumption and poor quality of life. TRIAL REGISTRATION NUMBER: NCT03417388.